GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular benefits, but the relationship between GLP-1RA and tumors is controversial. Recently, clinical trials reported higher rates of malignancy with semaglutide than control group. As real-world evidence of GLP-1RA-associated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zheng, Lv, Yuhuan, Yu, Meng, Mei, Mei, Xiang, Linyu, Zhao, Subei, Li, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640975/
https://www.ncbi.nlm.nih.gov/pubmed/36386208
http://dx.doi.org/10.3389/fphar.2022.925377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640975/
https://www.ncbi.nlm.nih.gov/pubmed/36386208
http://dx.doi.org/10.3389/fphar.2022.925377

Ejemplares similares